This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody & ADC Summit At ChinaBio
Shanghai, China
Kerry Hotel Pudong, Shanghai, ChinaApril 28–29, 2026
Book Now
Menu
Book
Key Sessions
John Zhu, PhD
Engineering the Next Frontier of ADCs: Deep Science Meets Global Clinical Scale
DualityBio
Noah Bindman, PhD
Insights from Two Decades of Clinical and Preclinical Experience with MMAE ADCs
Pfizer
Karen Silence, PhD
Developing a Pipeline Using FcRn Biology for Degradation of Pathogenic Antibodies
Argenx
Rongliang Lou, PhD
Bispecific and Dual-Payload Strategies for Developing Next-Generation ADCs
Innoventbio
keyboard_arrow_right

Day 2 - CT (China Time, GMT+08:00)

keyboard_arrow_leftSearch & Filter
search
Day 2 - CT (China Time, GMT+08:00)
search
Showing 1 of 1 Streams
08:00 - 08:55
Registration and Morning Coffee
08:55 - 09:00
Chairperson’s Remarks
09:00 - 09:30
Developing a Pipeline Using FcRn Biology for Degradation of Pathogenic Antibodies
  • Karen Silence, PhD - Head Preclinical Product Development, Argenx
09:30 - 10:00
Bispecific and Dual-Payload Strategies for Developing Next-Generation ADCs
  • Rongliang Lou, PhD - Executive Director, Innovative Drug Research Department, Innoventbio
Showing 1 of 1 Streams
10:00 - 10:30
Networking Refreshment Break with Poster and Exhibit Viewing
Showing 1 of 1 Streams
10:30 - 11:00
Engineering the Next Frontier of ADCs: Deep Science Meets Global Clinical Scale
  • John Zhu, PhD - Founder, Chairman & CEO, DualityBio
11:00 - 11:30
Insights from Two Decades of Clinical and Preclinical Experience with MMAE ADCs
  • Noah Bindman, PhD - Scientific Director of ADC Engineering, Pfizer
11:30 - 12:00
Late Breaking Presentation
12:00 - 12:30
Sponsored Scientific Briefing
Showing 1 of 1 Streams
12:30 - 13:40
Networking Luncheon
Showing 2 of 2 Streams
13:40 - 13:45
Chairperson’s Remarks
13:45 - 14:15
Complement Activation Limits the Agonistic Activity of Anti-OX40 Antibodies Engineered for Enhanced Fc-Fc Interaction-mediated Clustering
  • Bart-Jan de Kreuk, PhD - Associate Director, Antibody Format Discovery, Genmab
14:15 - 14:45
New Strategies for Targeted Cancer Immunotherapy
  • Zhenhua Ren, PhD - Research Professor, Changping Laboratory
14:45 - 15:15
Sponsored Scientific Briefing
13:40 - 13:45
Chairperson’s Remarks
13:45 - 14:15
Innovative Technologies and Development Strategies for Antibody-Oligonucleotide Conjugates (AOCs)
  • Hanhua Huang, PhD - Vice President, Biology, Avidity Biosciences
14:15 - 14:45
Alluminox Photoimmunotherapy: Advancing Cure While Preserving Quality of Life
  • Minami Maeda - President, Rakuten Medical
14:45 - 15:15
Sponsored Scientific Briefing
Showing 1 of 1 Streams
15:15 - 15:45
Networking Refreshment Break with Poster and Exhibit Viewing
Showing 2 of 2 Streams
15:45 - 16:15
AI/ML Based Design of a Novel FcγRIIb Selective Fc Domain to Enable S-4321: A Clinical Stage Dual Cell Bi-directional Antibody for Treating Cell Mediated Autoimmunity
  • Kevin Otipoby, PhD - Chief Research Officer, Seismic Therapeutics
16:15 - 16:45
FAST - Unlocking GPCR-Activating Antibodies with Library-scale Functional Data
  • Monica Schwartz, PhD - Vice President of Antibody Discovery, Abalone Bio
16:45 - 17:15
The NovoBody Platform: Computational Design of Next-Generation Single-Chain Antibodies
  • Alfredo Quijano Rubio, PhD - Co-founder and Chief Scientific Officer, Monod Bio
15:45 - 16:15
The Multimodal Development of Her2 Targeted Therapeutics
  • Ting Xu, PhD - Founder, Chairman & CEO, AlphaMab Oncology
16:15 - 16:45
Non-internalizing ADC Technology Development and Product Development
  • Jiaqiang Cai, PhD - Co-founder, CSO and Co-CEO, MediLink Therapeutics
16:45 - 17:15
A Novel bsADC for Glioblastoma (GBM)
  • Shuhua Xia, PhD - CEO, Nanjing Diligene Biotechnologies
Day 1
Filter
Streams
Formats
Choose Day